BioVector? KMCH-1 Human Combined Hepatocellular-Cholangiocarcinoma Cell Line / KMCH-1 人肝細(xì)胞-膽管細(xì)胞混合癌細(xì)胞株

一 產(chǎn)品基本信息與細(xì)胞生物學(xué)背景

• 細(xì)胞名稱：KMCH-1（常用別名包括：KMCH1、KMCH_1）。

• 物種來源：人類（Homo sapiens），供體為一名52歲的男性患者。

• 組織源起：源自原發(fā)性肝臟部位的惡性腫瘤組織（Primary Liver Tumor），經(jīng)體外原代分離建立。

• 腫瘤病理學(xué)分類（罕見的“混合型”標(biāo)桿模型）：

  KMCH-1 是全球肝膽腫瘤轉(zhuǎn)化醫(yī)學(xué)研究中極為罕見且珍貴的人原發(fā)性混合型肝細(xì)胞-膽管細(xì)胞癌（Combined Hepatocellular-Cholangiocarcinoma, cHCC-CCA 或 CHC）細(xì)胞模型。在病理切片和克隆演變中，該細(xì)胞展現(xiàn)出獨(dú)特的雙向分化表型，即同時具備肝細(xì)胞癌（HCC）的腺泡/條索狀特征和膽管細(xì)胞癌（CCA/ChC）的間質(zhì)促纖維化及腺管樣構(gòu)型。

• 核心表型、異質(zhì)性與干細(xì)胞標(biāo)記物（質(zhì)控數(shù)據(jù)）：

  • 上皮樣單層貼壁：形態(tài)學(xué)上主要表現(xiàn)為經(jīng)典的多角形上皮樣（Epithelial-like）形態(tài)，呈密集單層貼壁生長。

  • 雙向生物標(biāo)記物表達(dá)譜：KMCH-1 保留了雙向腫瘤抗原。它高表達(dá)膽管上皮特異性標(biāo)記物細(xì)胞角蛋白7（Cytokeratin 7, K7）、細(xì)胞角蛋白19（K19）以及 ABCG2。同時，在特定亞群中保留了產(chǎn)生甲胎蛋白（AFP）的潛能。

  • 干細(xì)胞亞群異質(zhì)性（核心分選特征）：研究證實(shí) KMCH-1 群體內(nèi)部存在顯著的肝上皮干/祖細(xì)胞（HSPC）樣層級異質(zhì)性：

    • $\text{EpCAM}^+$（上皮細(xì)胞粘附分子陽性）亞群：高表達(dá) K19 mRNA，不表達(dá) AFP，在裸鼠體內(nèi)接種具有極高的致瘤性，且能同時分化發(fā)育出 CCA 樣和 HCC 樣的混合癌組織。

    • $\text{EpCAM}^-$ 亞群：特異性表達(dá) AFP mRNA，不表達(dá) K19，體內(nèi)接種傾向于僅形成單純的 HCC 樣腫瘤。

  • 白介素-6（IL-6）自分泌環(huán)路：KMCH-1 能夠高度組成性分泌 IL-6（Constitutive IL-6 secretion）。其細(xì)胞膜表面擁有完整的 IL-6 受體復(fù)合物（IL-6R/gp130），在受到炎性因子（如 TNF-$\alpha$ 或 IL-1$\beta$）刺激時會進(jìn)一步觸發(fā)爆發(fā)式分泌，通過旁分泌/自分泌機(jī)制極強(qiáng)地激活下游的 p44/p42 MAPK 和 p38 MAPK 信號通路，維持其惡性增殖。

• 致瘤性與惡性度：在軟瓊脂中具有克隆形成能力，接種于無毛裸鼠（Nude mice）皮下極易形成高度擬真的異質(zhì)性異種移植瘤（Xenograft）。

二 核心科研價值與轉(zhuǎn)化醫(yī)學(xué)應(yīng)用

由于混合型肝癌（cHCC-CCA）臨床預(yù)后極差且缺乏統(tǒng)一的靶向治療標(biāo)準(zhǔn)，KMCH-1 具有不可替代的藥理學(xué)研究價值：

1. 肝膽雙特征腫瘤異質(zhì)性與靶向/免疫聯(lián)合化療藥物篩選：

   用于評估小分子多靶點(diǎn)酪氨酸激酶抑制劑（TKIs，如索拉非尼、侖伐替尼）或針對免疫檢查點(diǎn)（PD-1/PD-L1）的靶向藥物，在面對同時含有 HCC 和 CCA 兩種抗藥因子的混合腫瘤時的聯(lián)合殺傷效率。

2. IL-6 驅(qū)動型炎癥轉(zhuǎn)導(dǎo)機(jī)制與腫瘤微環(huán)境（TME）阻斷研究：

   KMCH-1 是研究“炎-癌轉(zhuǎn)化”機(jī)制的理想工具。常用于測試 IL-6 中和抗體、JAK/STAT 抑制劑或 MAPK 通路阻斷劑（如 PD098059）對切斷該癌細(xì)胞自分泌促生長環(huán)路、誘導(dǎo)細(xì)胞凋亡的有效性。

3. 腫瘤干細(xì)胞（CSC）分化與定向重塑研究：

   利用其 $\text{EpCAM}^+$ 祖細(xì)胞亞群，探索小分子化合物、非編碼 RNA 或表觀遺傳修飾劑能否誘導(dǎo)其發(fā)生分化阻斷，或者將其逆轉(zhuǎn)為低惡性度的單一分化類型。

三 實(shí)驗室細(xì)胞復(fù)蘇、高效傳代與長期保存標(biāo)準(zhǔn)步驟

1. 專用完全培養(yǎng)基配方與生長環(huán)境

• 基礎(chǔ)培養(yǎng)基：高質(zhì)量高糖 DMEM（含 L-谷氨酰胺）或高級 RPMI-1640。

• 完全培養(yǎng)基典型配方：

  • 高糖 DMEM 或 RPMI-1640 基礎(chǔ)培養(yǎng)基

  • 加 10% 優(yōu)質(zhì)胎牛血清（FBS）。

  • 加 1% 青霉素-鏈霉素雙抗。

  • 可選添加：1% 丙酮酸鈉（Sodium Pyruvate）和 1% 非必需氨基酸（NEAA）以維持其復(fù)雜的上皮代謝環(huán)境。

• 培養(yǎng)物理參數(shù)：標(biāo)準(zhǔn) 37 攝氏度，恒溫高濕度飽和，含 5% 二氧化碳（$CO_2$） 的無菌常規(guī)孵箱。

2. 冷凍細(xì)胞的復(fù)蘇與貼壁接種

1. 提前在無菌安全柜中向 T25 培養(yǎng)瓶內(nèi)注入 5 mL 預(yù)熱至 37 ℃ 的完全培養(yǎng)基。

2. 從液氮罐中取出 KMCH-1 凍存管，立刻全量投入 37 ℃ 恒溫水浴箱中，快速用力搖晃，在 1 分鐘內(nèi)使其完全融化。

3. 用 75% 酒精噴灑消毒外壁后移入安全柜。

4. 將細(xì)胞懸液緩慢滴加至盛有 4 mL 預(yù)熱完全培養(yǎng)基的 15 mL 離心管中，輕柔混勻。

5. 以 1000 rpm（約 200 g）離心 5 分鐘。

6. 抽干含有 DMSO 的上清液，加入 1 - 2 mL 完全培養(yǎng)基輕柔重懸胞泥。

7. 接種至 T25 瓶中，十字搖勻，置于 37 ℃ 孵箱中培養(yǎng)。24 小時后觀察細(xì)胞貼壁匯合度并徹底更換一次新鮮培養(yǎng)基，去除殘余碎屑。

3. 日常貼壁常規(guī)傳代操作流程

• 傳代時機(jī)：KMCH-1 呈典型的密集多角形上皮樣單層排列。當(dāng)細(xì)胞密度達(dá)到 80% - 90% 匯合度 時必須傳代。該細(xì)胞生長較為旺盛，通常每 3 - 4 天需要傳代一次。避免讓細(xì)胞過度長滿（$\gt 95\%$），否則由于高度接觸抑制和 IL-6 濃度過載，細(xì)胞會開始形成多層重疊生長并發(fā)生表型老化。

• 操作傳代步驟：

  1. 吸除舊培養(yǎng)基，用無菌 PBS 緩沖液輕輕漂洗細(xì)胞表面 1 次以洗凈殘余血清。

  2. 加入適量 0.25% Trypsin - 0.02% EDTA 消化液（T25 瓶常規(guī)加入 1 mL），使其均勻覆蓋細(xì)胞層，置于 37 ℃ 孵箱中消化。

  3. 倒置顯微鏡下嚴(yán)格動態(tài)觀察：由于其上皮粘附特性，通常需要消化 2 - 4 分鐘。當(dāng)觀察到絕大部分多角形細(xì)胞回縮變圓、胞間縫隙明顯增大、輕敲瓶身可見細(xì)胞成片松動脫落時，必須立刻倒入 2 倍體積的含血清完全培養(yǎng)基終止消化。

  4. 用移液槍輕柔吹打瓶壁 3 - 4 次，將貼壁細(xì)胞徹底打散，調(diào)理成均勻的單細(xì)胞懸液（注意避免過度用力吹打產(chǎn)生大量氣泡，氣泡產(chǎn)生的剪切力會損傷癌細(xì)胞表面受體）。

  5. 收集懸液，1000 rpm 離心 5 分鐘，棄上清。

  6. 加入新鮮完全培養(yǎng)基重懸，按照 1:3 至 1:4 的常規(guī)比例傳代，接種至新培養(yǎng)瓶中，補(bǔ)足培養(yǎng)基放回孵箱。

4. 模型穩(wěn)定性與質(zhì)控防線

1. 防范交叉污染（Cross-contamination Control）：KMCH-1 作為增殖極其活躍的實(shí)體瘤細(xì)胞，在長期傳代中必須嚴(yán)格與大腸癌細(xì)胞（如 HCT116）或常規(guī)高生長細(xì)胞（如 HeLa）隔開操作，每 10 - 15 代應(yīng)定期進(jìn)行 STR（短串聯(lián)重復(fù)序列）基因分型鑒定，確保該混合型肝癌的特異性遺傳本底未發(fā)生改變。

2. 分化狀態(tài)監(jiān)控：如果長期維持在高密度狀態(tài)下傳代，可能會導(dǎo)致 $\text{EpCAM}^+$ 祖細(xì)胞亞群自發(fā)耗竭或完全向 HCC 樣單向轉(zhuǎn)化。實(shí)驗中若發(fā)現(xiàn)細(xì)胞形態(tài)由緊密的多角形逐漸完全變成松散的長條異形，應(yīng)及時淘汰并復(fù)蘇低代數(shù)種子。

5. 細(xì)胞長期保存標(biāo)準(zhǔn)

• 凍存液配方：55% 基礎(chǔ) DMEM/RPMI-1640 培養(yǎng)基 + 35% 優(yōu)質(zhì)胎牛血清（FBS）+ 10% 分析級二甲基亞砜（DMSO）；或者使用高保護(hù)性的商業(yè)化無血清細(xì)胞凍存液。

• 冷凍梯度降溫規(guī)范：

  1. 收集處于對數(shù)生長最旺盛期（匯合度約 80%）、未老化的健康 KMCH-1 細(xì)胞，離心吸除上清。

  2. 用配制好的凍存液重懸，調(diào)整細(xì)胞終密度至 每毫升 1.5×10? 至 3×10? 個活細(xì)胞。

  3. 分裝入無菌凍存管，擰緊后立刻放入標(biāo)準(zhǔn)程序降溫盒（Mr. Frosty）。

  4. 將降溫盒投入 -80 ℃ 超低溫冰箱中慢速梯度降溫過夜（確保維持 $-1\text{ }^\circ\text{C/min}$ 的標(biāo)準(zhǔn)降溫速率）。

  5. 24 小時內(nèi)，迅速將凍存管轉(zhuǎn)移并鎖死在液氮罐（-196 ℃）中實(shí)施長期封存。禁止在 -80 ℃ 冰箱中長期擱置，以確保復(fù)蘇時異質(zhì)性干細(xì)胞亞群的存活率和雙向分化潛能不受破壞。

Part 2 English Section

I Product General Information and Cell Biological Background

• Cell Line Name: KMCH-1 (Alternative nomenclature: KMCH1, KMCH_1).

• Organism Source: Human (Homo sapiens), isolated from a 52-year-old male donor.

• Tissue Extract: Primary malignant tumor tissue biopsied from the liver mass.

• Tumor Pathological Classification (A Rare "Mixed-Type" Benchmark):

  KMCH-1 represents a globally distinct, highly valued cell model for investigating primary human Combined Hepatocellular-Cholangiocarcinoma (cHCC-CCA or CHC).

  In histopathological profiling and clonal selection, this cell line preserves a dual-lineage differentiation phenotype, mimicking tumors that simultaneously present areas of typical Hepatocellular Carcinoma (HCC) and Cholangiocarcinoma (CCA/ChC) embedded within a desmoplastic stroma.

• Core Phenotype, Heterogeneity, and Progenitor Footprint:

  • Epithelial Monolayer Growth: Exhibits a classic polygonal epithelial-like morphology, proliferating as a cohesive, adherent monolayer under standard conditions.

  • Bilineage Biomarker Expression Profile: KMCH-1 constitutively retains hepatobiliary tumor antigens. It strongly expresses cholangiocyte-specific markers Cytokeratin 7 (K7), Cytokeratin 19 (K19), and ABCG2, while maintaining the capacity to synthesize Alpha-Fetoprotein (AFP) within designated subsets.

  • Stem Cell Sub-Population Heterogeneity: Research confirms a clear hepatic stem/progenitor cell (HSPC) hierarchy within KMCH-1 cultures:

    • $\text{EpCAM}^+$ Sub-population: Expresses K19 mRNA but lacks AFP. It displays enhanced tumorigenicity in nude mice, regenerating mixed tumors containing both ChC and HCC-like components.

    • $\text{EpCAM}^-$ Sub-population: Selectively expresses AFP mRNA but lacks K19. Upon inoculation, it produces tumors restricted solely to an HCC-like lineage.

  • Autocrine Interleukin-6 (IL-6) Signaling Loop: KMCH-1 cells exhibit constitutive IL-6 secretion. They express functional IL-6 receptor complexes (IL-6R/gp130) on their plasma membrane. Exposure to inflammatory cytokines (e.g., TNF-$\alpha$ or IL-1$\beta$) drives an autocrine and paracrine cascade, activating downstream p44/p42 MAPK and p38 MAPK pathways to fuel malignant cell division.

• Tumorigenic Potential: Demonstrates high colony-forming efficiency in soft agar and rapidly generates highly representative heterogeneous xenografts when injected subcutaneously into athymic nude mice.

II Strategic Research Value and Translational Applications

Because combined liver cancer (cHCC-CCA) is clinically aggressive and lacks standardized target therapies, KMCH-1 serves as a critical pharmaceutical discovery platform:

1. Screening Targeted and Immune Combination Chemotherapies:

   Used to assess the efficacy of small-molecule multikinase inhibitors (e.g., Sorafenib, Lenvatinib) combined with immune checkpoint inhibitors (anti-PD-1/PD-L1) against mixed tumors that contain multiple drug-resistance factors.

2. Dissecting IL-6 Driven Inflammation Signaling Pathways:

   An optimal tool for studying inflammation-associated tumorigenesis. It is widely applied to test whether IL-6 neutralizing antibodies, JAK/STAT inhibitors, or MAPK pathway blockers (e.g., PD098059) can disrupt the cell's autocrine loop and trigger programmed cell death.

3. Cancer Stem Cell (CSC) Differentiation and Plasticity:

   Utilizing the $\text{EpCAM}^+$ progenitor pool, researchers evaluate whether small molecules, non-coding RNAs, or epigenetic modulators can block self-renewal or force differentiation into a single, less aggressive lineage.

III Laboratory Thawing, Passaging, and Cryopreservation Protocols

1. Basal Media Optimization and Environmental Parameters

• Basal Medium Base: High-quality High-Glucose DMEM (fortified with L-Glutamine) or premium RPMI-1640.

• Complete Growth Matrix Formulation:

  • High-Glucose DMEM or RPMI-1640 basal template

  • Supplemented with 10% premium Fetal Bovine Serum (FBS).

  • Fortified with 1% standard Penicillin-Streptomycin dual antibiotic cocktail.

  • Optional: 1% Sodium Pyruvate and 1% Non-Essential Amino Acids (NEAA) to support its complex epithelial metabolic requirements.

• Physical Processing Constants: Incubate strictly at 37 °C, packed with 5% Carbon Dioxide ($CO_2$) under continuous humified saturation conditions.

2. Cryovial Thawing and Recovery Protocol

1. Pre-warm a sterile T25 culture flask filled with 5 mL of complete growth medium to 37 °C inside the biosafety workstation.

2. Retrieve the KMCH-1 cryovial from liquid nitrogen and submerge it instantly within a 37 °C water bath. Agitate continuously to melt the internal matrix within 60 seconds.

3. Mist the exterior shell with 75% ethanol before transfer into the sterile workstation.

4. Draw up the liquid and transfer it slowly into a 15 mL conical tube containing 4 mL of pre-warmed complete growth medium to dilute the toxic DMSO footprint.

5. Centrifuge the suspension at 1000 rpm (~200 g) for 5 minutes.

6. Aspirate the supernatant completely, and gently resuspend the cell pellet in 1 - 2 mL of fresh complete growth medium.

7. Dispense the suspension into the prepared T25 flask, mix gently in a cross pattern, and incubate at 37 °C. Perform a complete medium change after 24 hours to remove residual cell debris and unattached elements.

3. Routine Adherent Passaging Workflow

• Confluency Assessment Control: Passaging workflows must be initialized when the adherent polygonal epithelial monolayer achieves 80% – 90% confluency. The line proliferates actively, typically requiring passaging every 3 to 4 days. Do not allow cultures to become over-confluent ($\gt 95\%$); dense cultures trigger contact inhibition and excessive IL-6 accumulation, causing multi-layered cell stacking and phenotypic aging.

• Passaging Execution Steps:

  1. Aspirate the spent growth fluid and wash the monolayer once with sterile, calcium/magnesium-free PBS, then discard the wash.

  2. Apply an appropriate layer of 0.25% Trypsin - 0.02% EDTA solution (typically 1 mL for a T25 format) and incubate at 37 °C.

  3. Microscopic Tracking: Monitor continuously under an inverted microscope. Due to strong epithelial adhesion properties, trypsinization typically requires 2 – 4 minutes at 37 °C. The moment the polygonal cells contract, intercellular spaces widen, and sheets loosen upon gentle tapping, add 2 volumes of serum-fortified complete growth medium to halt enzymatic cleavage.

  4. Gently pipette the suspension 3 to 4 times against the flask wall to dissociate clusters into a single-cell suspension. Avoid vigorous pipetting to prevent bubbles, which generate shear forces that can damage cell surface receptors.

  5. Collect the suspension, centrifuge at 1000 rpm for 5 minutes, and discard the supernatant.

  6. Resuspend the pellet in fresh complete growth medium and split the culture using standard ratios of 1:3 to 1:4. Seed into new flasks, top off with complete medium, and return to the incubator.

4. Model Fidelity and Quality Assurance Safeguards

1. Cross-contamination Safeguards: Because KMCH-1 is a highly proliferative tumor line, it must be handled separately from other rapidly growing lines (such as HCT116 or HeLa) to avoid cross-contamination. Perform STR (Short Tandem Repeat) profiling every 10 to 15 passages to verify its unique genetic background.

2. Phenotypic Drift Monitoring: Sustained cultivation at excessive densities can cause the spontaneous loss of the $\text{EpCAM}^+$ progenitor pool, driving a unidirectional shift toward a pure HCC-like phenotype. If the cells lose their tight polygonal shape and become elongated or fibroblastic, discard the batch and re-thaw a fresh low-passage vial.

5. Long-Term Cryopreservation Parameters

• Cryoprotectant Preservation Formula: 55% basal DMEM/RPMI-1640 growth medium + 35% premium Fetal Bovine Serum (FBS) + 10% analytical-grade Dimethyl Osmoxide (DMSO), or a certified high-protection commercial serum-free freezing matrix.

• Controlled Gradient Freezing Protocol:

  1. Harvest highly viable, mid-log phase cultures (approximately 80% confluent), ensuring the cells are non-senescent. Centrifuge and isolate the pellet.

  2. Resuspend the cells in the pre-chilled cryoprotectant matrix, adjusting the target density to between 1.5×10? and 3×10? viable cells per milliliter.

  3. Transfer the solution into sterile cryovials, tightening the caps securely. Place them immediately into a standard controlled-rate cooling container (e.g., Mr. Frosty).

  4. Deposit the container inside a -80 °C ultra-low freezer overnight to execute a steady cooling rate of -1 °C/minute.

  5. Within 24 hours, transfer the vials into liquid nitrogen storage tanks (-196 °C) for long-term preservation. Do not store vials long-term at -80 °C; tight temperature regulation is mandatory to preserve the survival rate and dual-differentiation potential of its sensitive progenitor cell fractions.

BioVector NTCC質(zhì)粒載體菌株細(xì)胞蛋白抗體基因保藏中心

電話:400-800-2947

工作QQ/微信同號:1843439339

網(wǎng)址http://www.nedfriskphoto.com